A Phase II Trial of AK104 in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-03-20
Target enrollment:
Participant gender:
Summary
Phase II open label, multicenter study to evaluate the efficacy and safety of AK104
(anti-PD-1 and CTLA-4 bispecific antibody) combined with Docetaxel in Advanced Non-Small Cell
Lung Cancer whose disease has progressed after prior platinum doublet chemotherapy and
anti-PD-1/PD-L1 monoclonal antibody